Mark Throsby
Amministratore Delegato presso Alethiomics Ltd.
Profilo
Mark Throsby is currently the CEO of Alethiomics Ltd.
He also holds positions as an Independent Director at Ona Therapeutics SL and as the Chief Operating & Scientific Officer at Gadeta BV.
Previously, he worked as the Director-Antibody Discovery at Crucell NV from 2000 to 2008 and as the Chief Scientific Officer & Executive VP at Merus NV from 2008 to 2020.
Dr. Throsby obtained a doctorate degree from Monash University.
Posizioni attive di Mark Throsby
Società | Posizione | Inizio |
---|---|---|
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Direttore/Membro del Consiglio | 05/03/2021 |
Alethiomics Ltd.
Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby. | Amministratore Delegato | - |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Direttore operativo | 01/10/2020 |
Precedenti posizioni note di Mark Throsby
Società | Posizione | Fine |
---|---|---|
MERUS N.V. | Direttore operativo | 01/01/2013 |
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Corporate Officer/Principal | 28/10/2008 |
Formazione di Mark Throsby
Monash University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
MERUS N.V. | Health Technology |
Aziende private | 4 |
---|---|
Crucell NV
Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Health Technology |
Alethiomics Ltd.
Alethiomics Ltd. Miscellaneous Commercial ServicesCommercial Services Alethiomics Ltd. operates as a British biotechnology company. The company is based in Cambridge, UK. The company was founded in 2021 by Adam Joseph Mead, Bethan Psaila. The CEO is Mark Throsby. | Commercial Services |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
- Borsa valori
- Insiders
- Mark Throsby